The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
News|Videos|February 3, 2025
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study
Author(s)Constantine S. Tam, MD, MBBS
Dr. Constantine S. Tam presents preliminary results from the Phase 1 CaDAnCe-101 study, highlighting the promising efficacy and safety of the BTK degrader BGB-16673 in heavily pretreated patients with relapsed or refractory CLL/SLL, including those with BTK inhibitor resistance and Richter transformation.
Advertisement
Advertisement
Related to this article
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5